Yiming Kale Biomedical Technology (Shanghai), an affiliate of Yiming Enko-B (01541), received a capital increase of 50 million yuan

Zhitong Finance App News, Yiming Angke-B (01541) issued an announcement. On August 6, 2026, the Company, Yiming Kyle Biomedical Technology (Shanghai) Co., Ltd. (target company, non-wholly-owned subsidiary of the Company), Jiaxing Zhang Keling Yishengke Venture Capital Partnership (Limited Partnership) (Biotech Launch), Suzhou New Territories Chuangyuan Enterprise Management Partnership (Limited Partnership) (New Territories Chuangyuan) and Mr. Wang Xueyan (Mr. Wang, collectively referred to as “investors”) with Biotech Sailing and New Territories Chuangyuan Asset agreements.

According to the capital increase agreement, the investors agreed to pay a total consideration of RMB 50 million to increase the registered capital of RMB 465,000, accounting for about 15.83% of the expanded shares of the target company. At the same time as the capital increase was being carried out, through an agreement between the Company and the target company, the target company owed the company's outstanding principal amount and accrued interest of RMB 15.86 million under the existing loan, which will be converted to RMB 147,500 of the target company's expanded registered capital according to the pledge price per registered capital of the investor applicable to the investor as stipulated in the capital increase agreement.

Our company is a clinical-stage biotechnology company dedicated to developing cancer immunotherapy. Target Company is an innovative drug research and development company focused on developing innovative drugs for metabolic diseases and rare diseases. By introducing external professional investors, the capital increase not only provides the target company with additional funding channels and strengthens its overall financial strength, but also brings industry experience, strategic resources and networking, and promotes the target company to continue to carry out R&D work. The Company believes that the capital increase and the proposed transactions under it are in line with the Group's long-term strategic development goals and are expected to enhance the financial strength of the target company.